Literature DB >> 33342465

How handling extreme C-reactive protein (CRP) values and regularization influences CRP and depression criteria associations in network analyses.

Daniel P Moriarity1, Sarah R Horn2, Marin M Kautz3, Jonas M B Haslbeck4, Lauren B Alloy3.   

Abstract

Increasingly, it has been recognized that analysis at the symptom, rather than diagnostic, level will drive progress in the field of immunopsychiatry. Network analysis offers a useful tool in this pursuit with the ability to identify associations between immune markers and individual symptoms, independent of all other variables modeled. However, investigation into how methodological decisions (i.e., including vs. excluding participants with C-reactive protein (CRP) >10 mg/L, regularized vs. nonregularized networks) influence results is necessary to establish best practices for the use of network analysis in immunopsychiatry. In a sample of 3,464 adult participants from the 2015-2016 National Health and Nutrition Examination Survey dataset, this study found consistent support for associations between CRP and fatigue and changes in appetite and some support for additional CRP-criterion associations. Methodologically, results consistently demonstrated that including individuals with CRP >10 mg/L and estimating nonregularized networks provided better estimates of these associations. Thus, we recommend considering the use of nonregularized networks in immunopsychiatry and inclusion of cases with CRP values >10 mg/L when testing the association between CRP and depression criteria, unless contraindicated by the research question being tested. Additionally, results most consistently suggest that CRP is uniquely related to fatigue and changes in appetite, supporting their inclusion in an immunometabolic phenotype of depression. Finally, these associations suggest that fatigue and changes in appetite might be particularly receptive to anti-inflammatory treatments. However, future research with more nuanced measures is necessary to parse out whether appetite increases or decreases drive this association. Further, longitudinal research is an important next step to test how these relationships manifest over time.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C-reactive Protein; CRP; Depression; Inflammation; Network analysis; Phenotype; Replication; Transdiagnostic

Mesh:

Substances:

Year:  2020        PMID: 33342465      PMCID: PMC7753060          DOI: 10.1016/j.bbi.2020.10.020

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  64 in total

1.  Replication and reproducibility issues in the relationship between C-reactive protein and depression: A systematic review and focused meta-analysis.

Authors:  Sarah R Horn; Madison M Long; Benjamin W Nelson; Nicholas B Allen; Philip A Fisher; Michelle L Byrne
Journal:  Brain Behav Immun       Date:  2018-06-19       Impact factor: 7.217

2.  On Nonregularized Estimation of Psychological Networks.

Authors:  Donald R Williams; Mijke Rhemtulla; Anna C Wysocki; Philippe Rast
Journal:  Multivariate Behav Res       Date:  2019-04-08       Impact factor: 5.923

3.  Clustering of depression and inflammation in adolescents previously exposed to childhood adversity.

Authors:  Gregory E Miller; Steve W Cole
Journal:  Biol Psychiatry       Date:  2012-04-10       Impact factor: 13.382

Review 4.  Beyond diagnoses and total symptom scores: Diversifying the level of analysis in psychoneuroimmunology research.

Authors:  Daniel P Moriarity; Lauren B Alloy
Journal:  Brain Behav Immun       Date:  2020-07-18       Impact factor: 7.217

5.  Exacerbated fatigue and motor deficits in interleukin-10-deficient mice after peripheral immune stimulation.

Authors:  C P Krzyszton; N L Sparkman; R W Grant; J B Buchanan; S R Broussard; J Woods; R W Johnson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-07-23       Impact factor: 3.619

6.  Levers and barriers to success in the use of translational neuroscience for the prevention and treatment of mental health and promotion of well-being across the lifespan.

Authors:  Sarah R Horn; Philip A Fisher; Jennifer H Pfeifer; Nicholas B Allen; Elliot T Berkman
Journal:  J Abnorm Psychol       Date:  2020-01

7.  Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study.

Authors:  Golam M Khandaker; Rebecca M Pearson; Stanley Zammit; Glyn Lewis; Peter B Jones
Journal:  JAMA Psychiatry       Date:  2014-10       Impact factor: 21.596

8.  Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder.

Authors:  Rita Haapakoski; Julia Mathieu; Klaus P Ebmeier; Harri Alenius; Mika Kivimäki
Journal:  Brain Behav Immun       Date:  2015-06-09       Impact factor: 7.217

9.  Repeated exposure to systemic inflammation and risk of new depressive symptoms among older adults.

Authors:  J A Bell; M Kivimäki; E T Bullmore; A Steptoe; L A Carvalho
Journal:  Transl Psychiatry       Date:  2017-08-15       Impact factor: 6.222

10.  Longitudinal association between inflammatory markers and specific symptoms of depression in a prospective birth cohort.

Authors:  Alexander L Chu; Jan Stochl; Glyn Lewis; Stan Zammit; Peter B Jones; Golam M Khandaker
Journal:  Brain Behav Immun       Date:  2018-11-07       Impact factor: 7.217

View more
  10 in total

1.  Statistical Relationship Networks in Psychiatric Research: The Case of Delirium in the Context of Covid-19.

Authors:  Cristian Ramos-Vera
Journal:  Rev Colomb Psiquiatr (Engl Ed)       Date:  2021-03-12

Review 2.  Major Depressive Disorder in Older Patients as an Inflammatory Disorder: Implications for the Pharmacological Management of Geriatric Depression.

Authors:  Malcolm P Forbes; Adrienne O'Neil; Melissa Lane; Bruno Agustini; Nick Myles; Michael Berk
Journal:  Drugs Aging       Date:  2021-04-29       Impact factor: 3.923

Review 3.  A primer on common analytic concerns in psychoneuroimmunology: Alternatives and paths forward.

Authors:  Daniel P Moriarity
Journal:  Brain Behav Immun       Date:  2022-03-17       Impact factor: 7.217

4.  C-Reactive protein concentrations in reproductive-aged women with major mood disorders.

Authors:  Elizabeth Torres; Katelynn B Zumpf; Jody D Ciolino; Crystal T Clark; Dorothy K Sit; Emily S Miller; Katherine L Wisner
Journal:  Arch Womens Ment Health       Date:  2022-03-22       Impact factor: 3.633

Review 5.  Diagnoses Based on C-Reactive Protein Point-of-Care Tests.

Authors:  Miroslav Pohanka
Journal:  Biosensors (Basel)       Date:  2022-05-17

6.  Women with lower systemic inflammation demonstrate steeper cognitive decline with age: Results from a large prospective, longitudinal sample.

Authors:  Melody Moloci Noss; Summer N Millwood; Kate R Kuhlman
Journal:  Brain Behav Immun Health       Date:  2022-05-02

7.  Inflammatory phenotype of depression symptom structure: A network perspective.

Authors:  Daniel P Moriarity; Claudia van Borkulo; Lauren B Alloy
Journal:  Brain Behav Immun       Date:  2020-12-09       Impact factor: 7.217

8.  Personality pathways to mortality: Interleukin-6 links conscientiousness to mortality risk.

Authors:  Páraic S O'Súilleabháin; Nicholas A Turiano; Denis Gerstorf; Martina Luchetti; Stephen Gallagher; Amanda A Sesker; Antonio Terracciano; Angelina R Sutin
Journal:  Brain Behav Immun       Date:  2021-02-09       Impact factor: 7.217

9.  Difficulties in psychosocial functioning due to current depressive symptoms: What can C-Reactive protein tell us?

Authors:  Jay D O'Shields; Orion P Mowbray
Journal:  Brain Behav Immun Health       Date:  2021-07-30

10.  Association of inflammation with depression and anxiety: evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts.

Authors:  Yuri Milaneschi; Nils Kappelmann; Zheng Ye; Femke Lamers; Sylvain Moser; Peter B Jones; Stephen Burgess; Brenda W J H Penninx; Golam M Khandaker
Journal:  Mol Psychiatry       Date:  2021-06-16       Impact factor: 15.992

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.